Compare ZH & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZH | NGNE |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.3M | 327.8M |
| IPO Year | 2021 | N/A |
| Metric | ZH | NGNE |
|---|---|---|
| Price | $3.54 | $17.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $40.14 |
| AVG Volume (30 Days) | ★ 311.4K | 111.0K |
| Earning Date | 03-25-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $416,437,241.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.23 | $6.88 |
| 52 Week High | $6.32 | $37.27 |
| Indicator | ZH | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 45.98 |
| Support Level | $3.41 | $16.20 |
| Resistance Level | $3.76 | $17.95 |
| Average True Range (ATR) | 0.17 | 1.36 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 25.49 | 34.81 |
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.